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Abstract: 
As part of our ongoing isolation of cholinesterase (ChE) and β-site amyloid precursor protein (APP) cleaving 
enzyme 1 (BACE1) inhibitors from natural sources, the bioactivity of the ethanolic extracts was screened for 
their inhibitory activities against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and BACE1. 
Ocimum sanctum exhibited promising inhibitory activity against AChE, BChE, BACE1 and peroxynitrite 
(ONOO-). Among the different solvent-soluble fractions obtained from the ethanolic extract, the 
dichloromethane (CH2Cl2) fraction was found to cause the most potent scavenging, or inhibitory activities, 
against peroxynitrite (ONOO-) with the respective IC50 values of 1.21 ± 0.05 µg/mL. Likewise, the 
dichloromethane fraction also exhibited potent inhibitory activities against AChE, BChE and BACE1 with IC50 
values of 2.54 ± 0.03, 13.52 ± 0.13 and 3.05 ± 0.01 µg/mL, respectively. Silica gel column chromatography of 
the dichloromethane fraction yielded two flavonoids, Cirsilineol and Isothymusin, based on the comparison with 
reported 1H- and 13C-NMR spectroscopic data. All of the compounds displayed concentration dependent in vitro 
inhibitory activity toward the ChEs, BACE1 and peroxynitrite (ONOO-). Among them, Cirsilineol exhibited the 
potential inhibitory activity toward ChEs with the respective IC50 values of 2.95 ± 0.02 and 3.25 ± 0.08 µM, 
whereas the potential BACE1 inhibitor was Isothymusin with IC50 values of 4.45 ± 0.05 µM. In conclusion, we 
identified significant ChE and BACE1 inhibitors from Ocimum sanctum that could have value as new multi-
targeted compounds for anti-AD agents.  
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Alzheimer’s disease (AD) is one of the most 
common aging-related neurological disorders that 
usually starts slowly and gets worse over time. AD 
is correlated with the appearance of neurofibrillary 
tangles, senile plaques, and loss of neurons in the 
brain [1]. Although the exact mechanisms of the 
pathogenesis of this disease remain unclear, several 
competing hypotheses have been proposed, 
including cholinergic hypothesis and beta (β)-
amyloid cascade hypothesis. According to the 
cholinergic hypothesis, the memory impairment in 
AD results from the dysfunctions in the central 
cholinergic neurotransmission of acetylcholine 
[2,3]. In particular, cholinesterases (ChEs) serve as 
the key enzymes which highly implicated in the 
pathogenesis of AD [4]. The intracellular and 
extracellular accumulations of Aβ peptides are also 
believed to play a key role in AD [5,6]. Aβ is 
formed through the amyloidogenic pathway in 
which amyloid precursor protein (APP) is 
sequentially cleaved by β-site amyloid precursor 
protein cleaving enzyme 1 (BACE1) and γ-
secretase [7]. The proteolytic processing of APP 
increased the production and accumulation of 
neurotoxic forms of Aβ in the brain. 
A plenty of traditional herbal medicinal practices 
have been adopted for the diagnosis, prevention 
and treatment of Alzheimer disease. The Ocimum 
sanctum belonging to family Lamiaceae is 
medicinally used in diabetes, digestive, diuretic, 
cardiopathy, haemopathy, leucoderma, asthma, 
bronchitis, catarrhal fever, otalgia, hepatopathy, 
lumbago, ophthalmia, gastropathy in children, GIT 
disorders, ringworm, verminosis and skin disease 
[8-13]. O. sanctum also showed antioxidant, lipid-
lowering [14], anti-metastatic [15], antifungal [16], 
antibacterial [17], antimicrobial [18], wound 
healing [19] and neuroprotective [20] activities. 
However, there have been no studies on O. 
sanctum that show which active components are 
responsible for AChE, BChE, BACE1 as well as 
peroxynitrite (ONOO-)  inhibitory activities. The 
objective of the present study was to investigate the 
anti-alzheimer activity of the different fractions of 
the ethanolic extract of the leaves of O. sanctum 
using in vitro models. Our data suggest that O. 
sanctum may perhaps represent a source of new 
way for the prevention and treatment of neuronal 
disorders such as AD and oxidative damage-
associated diseases. 
 
MATERIALS AND METHODS: 
General Experimental Procedures 
Column chromatography was conducted using 
silica (Si) gel 60 (70–230 mesh, Merck, Darmstadt, 
Germany), Si gel 60 (230–400 mesh, Merck, 
Darmstadt, Germany), Sephadex LH20 (20–100 
µm, Sigma, St. Louis, MO, USA), Lichroprep RP-
18 (40–63 µm, Merck, Darmstadt, Germany). All 
thin layer chromatography (TLC) was conducted 
on pre-coated Merck Kiesel gel 60 F254 plates (20 × 
20 cm, 0.25 mm, Merck) and RP-18 F254S plates (5 
× 10 cm, Merck), using 10% H2SO4 as the spray 
reagent. 
 
Chemicals and Reagents 
Electric-eel AChE (EC 3.1.1.7), horse-serum BChE 
(EC 3.1.1.8), acetylthiocholine iodide (ACh), 
butyrylthiocholine chloride (BCh), 5,5′-dithiobis[2-
nitrobenzoic acid] (DTNB), eserine, L-
penicillamine (L-2-amino-3-mercapto-3-
methylbutanoic acid), and 
diethylenetriaminepentaacetic acid (DTPA) were 
purchased from Sigma (St. Louis, MO, USA). A 
BACE1 FRET assay kit (bsecretase) was purchased 
from PanVera Co. (Madison, WI, USA). High 
quality dihydrorhodamine 123 (DHR 123) was 
purchased from Molecular Probes (Eugene, OR, 
USA), and ONOO- was purchased from Cayman 
Chemicals Co. (Ann Arbor, MI, USA). All 
chemicals and solvents used in the assays were of 
reagent grade, and were purchased from 
commercial sources.  
 
Plant Material 
The plant sample of O. sanctum leaves were 
collected in July, 2016 from local area of 
Bangladesh. The plant was identified by 
Bangladesh National Herbarium, Dhaka, where a 
voucher specimen (20160720) has been deposited. 
At first, Leaves were washed properly to remove 
dirty materials and air-dried for several days. These 
were then ground with a hammer grinder for better 
grinding. The dried leaves were ground into a 
coarse powder. Then, the dried powder was 
preserved in an airtight container. 
 
Extraction, Fractionation and Isolation of O. 
sanctum 
Dried powder of O. sanctum was refluxed with 
70% EtOH (3 × 3 L) for 3 h, and each filtrate was 
concentrated until dry in vacuo at 400 C, resulting 
in EtOH extract (250.0 g). This extract was 
suspended in distilled H2O and then successively 
partitioned with CH2Cl2, EtOAc, and n-BuOH, to 
yield the CH2Cl2 (60.6 g), EtOAc (49.5 g), and n-
BuOH (30.6 g) fractions, respectively, as well as an 
H2O residue (92.0 g). The active CH2Cl2 fraction 
(60.6 g) obtained from O. sanctum was subjected to 
chromatography on a silica gel column, with 
CH2Cl2-MeOH (100:1 to 5:1) as the eluent, 
yielding eighteen subfractions (OS01-OS18). 
Repeated column chromatography of OS04 (10.30 
g) was conducted with a solvent mixture of CH2Cl2 
and MeOH, yielding ten subfractions (OS0401-
OS0410). OS0402 (0.23 g) was purified on an RP-
18 column and eluted with aqueous MeOH (20% 
MeOH-100 % MeOH, gradient elution) to yield 
flavonoid compound, Cirsilineol. Subfraction OS05 
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was similarly chromatographed and conducted with 
a solvent mixture of CH2Cl2 and MeOH, yielding 
eight subfractions (OS0501-OS0508). OS0503 
(0.35 g) was purified on an RP-18 column and 
eluted with aqueous MeOH (10% MeOH-100 % 
MeOH, gradient elution) to yield flavone 
compound, Isothymusin.  The chemical structure of 
this compound was identified by spectroscopic 
methods, including 1H- and 13C-NMR. The 
structure is shown in Fig. 1.  
Compound 1, (Cirsilineol): 1H NMR (500 MHz, 
acetone-d6): δ 12.96 (s, 1 H, 5-OH), 7.63 (m, 2 H, 
H-2′, 6′), 7.08 (d, J = 8.2 Hz, 1 H, H-5′), 6.84 (s, 1 
H, H-8), 6.74 (s, 1 H, H-3), 3.99 (s, 3 H, 3′-OMe), 
3.97 (s, 3 H, 7-OMe), 3.80 (s, 3 H, 6-OMe); 13C 
NMR (125 MHz, acetone-d6): δ 183.60 (C-4), 
165.27 (C-2), 160.13 (C-7), 154.13 (C-5), 154.01 
(C-9), 151.61 (C-4′), 148.98 (C-3′), 133.55 (C-6), 
123.60 (C-1′), 121.45 (C-6′), 116.47 (C-5′), 110.59 
(C-2′), 106.57 (C-10), 104.26 (C-3), 92.00 (C-8), 
60.60 (6-OMe), 56.87 (7-OMe), 56.68 (3′-OMe). 
Compound 2, (Isothymusin): 1HNMR (400 MHz, 
DMSO-d6): δ 3.80 (3H, s, 6-OMe), 3.92 (3H, s, 7-
OMe), 6.82 (1H, s, H-3), 6.92 (2×1H, d, J 8.7 Hz, 
H-3', H-5'), 8.01 (2×1H, d, J 8.7 Hz, H-2', H-6'), 
12.43 (1H, s, 5-OH); 13C-NMR (100 MHz, DMSO-
d6): δ 60.4 (6-OMe) 61.1 (8-OMe), 102.4 (C-3), 
106.3 (C-10), 115.9 (C-3', C-5'), 121.2 (C-1'), 
128.7 (C-2', C-6'), 130.6 (C-8), 136.1 (C-6), 141.3 
(C-9), 144.6 (C-5), 148.0 (C-7), 161.3 (C-4'), 164.2 
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In vitro ChEs inhibitory activity assay 
The inhibitory activities of ChEs were measured 
using the spectrophotometric method developed by 
Ellman et al. [21]. ACh and BCh were used as the 
substrates to assess the inhibitory activity of AChE 
and BChE, respectively. The reaction mixture 
contained: 140 mL of sodium phosphate buffer (pH 
8.0), 20 mL of test sample solution and 20 mL of 
either AChE or BChE solution, which were mixed 
and incubated for 15 min at room temperature. The 
reactions were then initiated with the addition of 10 
mL of DTNB, and 10 mL of either ACh or BCh. 
The hydrolysis of ACh or BCh was monitored by 
observing the formation of yellow 5-thio-2-
nitrobenzoate anion at 412 nm for 15 min. This 
anion forms as a result of the reaction between 
DTNB and thiocholine, and is released by the 
enzymatic hydrolysis of either ACh or BCh. All 
reactions were performed in triplicate in 96-well 
microplates using a VERSA max (Molecular 
Devices). The percentage (%) inhibition was 
calculated from (E–S)/E × 100, where E and S are 
the enzyme activities without and with the test 
sample, respectively. The ChEs-inhibiting activity 
of each sample was expressed in terms of the 50 % 
inhibition concentration (IC50) value (mg/mL or 
mM required to inhibit the hydrolysis of the 
substrate; ACh or BCh, by 50 %), as calculated 
from the log-dose inhibition curve. 
 
In vitro BACE1 enzyme assay 
Each assay was carried out according to the 
supplied instructions with selected modifications. 
Briefly, mixtures of 10 µL of assay buffer (50 mM 
sodium acetate, pH 4.5), 10 µL of BACE1 (1.0 
U/mL), 10 µL of the substrate (750 nM Rh-
EVNLDAEFK-Quencher in 50 mM, ammonium 
bicarbonate), and 10 µL of samples (final 
concentration, 250 µg/mL for the extracts/fractions; 
100 µM for the compounds) dissolved in 10 % 
DMSO were incubated for 60 min at 25 C in the 
dark. The proteolysis of two fluorophores (Rh-
EVNLDAEFK-Quencher) by BACE1 was 
monitored by formation of the fluorescent donor 
Rh-EVNL (530-545 nm, excitation; 570-590 nm, 
emission), the abundance of which was determined 
by measuring the increase in fluorescence excited 
at 545 nm and recorded at 585 nm. Fluorescence 
was measured with a microplate spectrofluorometer 
(Molecular Devices). The percent inhibition (%) 
was obtained by the following equation: % 
Inhibition = [1 - (S60 - S0)/(C60 - C0)] × 100, where 
C60 was the fluorescence of the control (enzyme, 
buffer, and substrate) after incubation for 60 min, 
C0 was the initial fluorescence of the control, S60 
was the fluorescence of the tested samples 
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incubation for 60 min, and S0 was the initial 
fluorescence of the tested samples. To account for 
the quenching effect of samples, the sample 
solution was added to a separate reaction mixture 
C, and any reduction in fluorescence by the sample 
was investigated. The BACE1 inhibitory activity of 
compounds was expressed in terms of the IC50 
value (µg/mL or µM required to inhibit proteolysis 
of the substrate, BACE1, by 50 %), as calculated 
from the log-dose inhibition curve. Quercetin was 
used as a positive control. 
 
Assay for ONOO- scavenging activity 
The ONOO- scavenging activity was assessed by 
the modified method of Kooy et al. [22], which 
involved monitoring highly fluorescent rhodamine 
123 that was rapidly produced from non-
fluorescent DHR 123 in the presence of ONOO-. In 
brief, the rhodamine buffer (pH 7.4) consisted of 
50 mM sodium phosphate dibasic, 50 mM sodium 
phosphate monobasic, 90 mM sodium chloride, 5.0 
mM potassium chloride, and 100 µM DTPA. The 
final DHR 123 concentration was 5.0 µM. The 
assay buffer was prepared prior to use and placed 
on ice. The background and final fluorescent 
intensities were measured 5 min after treatment 
with and without the addition of authentic ONOO- 
(10 µM) dissolved in 0.3 N sodium hydroxide. The 
fluorescence intensity of the oxidized DHR 123 
was evaluated using a fluorescence microplate 
reader (Bio-Tek Instruments Inc., FL 9 800, 
Winooski, UT, USA) at excitation and emission 
wavelengths of 480 and 530 nm, respectively. The 
values of the ONOO- scavenging activity were 
calculated as the final fluorescence intensity minus 
the background fluorescence, via detection of DHR 





One-way ANOVA and Student’s t test were used to 
determine the statistical significance of differences 
between values for various experimental and 
control groups (Systat; Evaston, IL, USA). Each 




AChE, BChE and BACE1 inhibitory activities 
of the EtOH extract and its solvent soluble 
fractions from O. sanctum 
To evaluate the anti-AD potential of O. sanctum, 
the EtOH extract was tested in in vitro 
AChE, BChE, and BACE1 inhibition assays. The 
inhibitory activities of the EtOH extract 
against AChE, BChE, and BACE1 are shown in 
Table 1. The EtOH extract showed potential 
inhibitory activity against AChE, BChE, and 
BACE1 with IC50 values of 11.42 ± 0.23, 93.04 ± 
0.43, and 90.43 ± 1.73 μg/mL compared to the 
positive controls of Berberine for ChEs (0.13 ± 
0.01 μg/mL for AChE, and 8.28 ± 0.22 μg/mL for 
BChE) and Quercetin for BACE1 (10.7 ± 0.17 
μg/mL). The EtOH extract of O. sanctum was 
dissolved in H2O and successively partitioned with 
CH2Cl2, EtOAc, and n-BuOH to obtain different 
solvent-soluble fractions, which were individually 
tested for AChE, BChE, and BACE1 inhibitory 
activity. As shown in Table 1, the CH2Cl2 and 
EtOAc fractions showed the highest AChE 
inhibitory activity with IC50 values of 2.54 ± 0.03 
and 13.26 ± 0.44 μg/mL, whereas the CH2Cl2 and 
EtOAc fractions also showed the potential BChE 
inhibitory activity with IC50 values of 13.52 ± 0.13 
and 19.56 ± 0.34 μg/mL respectively. Moreover, 
the CH2Cl2 fraction exhibited the highest BACE1 
inhibitory activity with an IC50 value of 3.05 ± 0.01 
μg/mL. 
 
Table 1: AChE, BChE and BACE1 inhibitory activities of the ethanolic extract and its solvent-soluble 
fractions from O. sanctum 
Extract/Fractions 
IC50 values (µg/mL)a ± SEM 
AChE BChE BACE1 
EtOH extract 11.42 ± 0.23 93.04 ± 0.43 90.43 ± 1.73 
CH2Cl2 fraction 2.54 ± 0.03 13.52 ± 0.13 3.05 ± 0.01 
EtOAc fraction 13.26 ± 0.44 19.56 ± 0.34 16.98 ± 0.27 
n-BuOH fraction 36.86 ± 0.70 42.94 ± 0.70 46.17 ± 0.47 
H2O fraction 49.81 ± 1.21 NA NA 
Berberineb 0.13 ± 0.01 8.28 ± 0.22  
Quercetinc   10.7 ± 0.17 
a The concentration that caused 50% inhibition (IC50) is given as the mean ± SEM of  triplicate experiments 
b Used as positive control in AChE and BChE inhibitory assay 
c Used as positive control in BACE1 inhibitory assay 
NA no activity in tested concentration 
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Table 2: Peroxynitrite (ONOO-) scavenging activities of the ethanolic extract and its solvent-soluble 
fractions from O. Sanctum 
 
Extract/Fractions 
IC50 values (µg/mL)a ± SEM 
Peroxynitrite (ONOO-) 
EtOH extract 8.81 ± 0.18 
CH2Cl2 fraction 1.21 ± 0.05 
EtOAc fraction 7.46 ± 0.16 
n-BuOH fraction 35.15 ± 0.23 
H2O fraction NA 
L-Penicillamineb 1.38 ± 0.08 
a The concentration that caused 50% inhibition (IC50) is given as the mean ± SEM of  triplicate experiments 
b Used as positive control in ONOO- scavenging assay 
NA no activity in tested concentration 
 
Table 3: Antioxidant and cholinesterase inhibitory activities of compounds isolated from O. Sanctum 
 
Compounds 
IC50 (µM) ± SEMa 
ONOO- AChE BChE BACE1 
Cirsilineol 2.85 ± 0.04 2.95 ± 0.02 3.25 ± 0.08 20.35 ± 0.21 
Isothymusin 5.49 ± 0.20 8.25 ± 0.13 7.85 ± 0.01 4.45 ± 0.05 
L-Penicillamineb 9.25 ± 0.61    
Berberinec  0.70 ± 0.21 11.64 ± 0.81  
Quercetined    9.85 ± 0.39 
a The concentration that caused 50% inhibition (IC50) is given as the mean ± SEM of  triplicate experiments 
b Used as positive control in ONOO- scavenging assay 
c Used as positive control in AChE and BChE inhibitory assay 
d Used as positive control in BACE1 inhibitory assay 
 
Peroxynitrite (ONOO-) scavenging activity of 
the EtOH extract as well as different fractions 
from O. sanctum 
Peroxynitrite (ONOO-) scavenging activities of the 
EtOH extract and its different solvent-soluble 
fractions of O. sanctum are presented in Table 2. 
CH2Cl2 fraction displaying the highest ONOO- 
inhibitory activity with an IC50 value of 1.21 ± 0.05 
µg/mL compared to the positive control L-
Penicillamine with an IC50 value of 1.38 ± 0.08 
µg/mL. In addition, the EtOAc and n-BuOH 
fractions also showed significance inhibitory 
activity with corresponding IC50 values of 7.46 ± 
0.16 and 35.15 ± 0.23 µg/mL, respectively, results 
were shown in table 2. 
 
Antioxidant and cholinesterase inhibitory 
activities of compound isolated from O. sanctum 
The inhibitory activities of the isolated compounds 
against AChE, BChE, BACE1 and ONOO- are 
expressed as IC50 values in Table 3. Among the 
tested compounds, Cirsilineol showed the most 
potent inhibitory activity against AChE and BChE 
with an IC50 value of 2.95 ± 0.02 µM and 3.25 ± 
0.08 µM, whereas berberine had an IC50 value of 
0.70 ± 0.21 µM for AChE and 11.64 ± 0.81 µM for 
BChE. Isothymusin also showed significant AChE 
as well as BChE inhibitory activity, with IC50 
values of 8.25 ± 0.13 µM and 7.85 ± 0.01 µM, 
respectively. Furthermore, Isothymusin displayed 
potent concentration-dependent inhibitors of 
BACE1, with IC50 values of 4.45 ± 0.05 µM, 
compared to the positive control quercetin, which 
had an IC50 value of 9.85 ± 0.39 µM. Cirsilineol 
also showed significance inhibitory activity against 
BACE1, with IC50 values of 20.35 ± 0.21 µM. In 
addition, both compounds exhibited significant 
inhibitory effects against ONOO-, with scavenging 
potencies as indicated by IC50 values of 2.85 ± 
0.04, and 5.49 ± 0.20 µM, respectively whereas 
IC50 values of the positive controls, L-
penicillamine was 9.25 ± 0.61 µM, results were 
shown in table 3.  
 
DISCUSSION: 
In 2015, 46.8 million people worldwide are living 
with AD. This number of AD patients will 
dramatically increase over every 20 years, reaching 
74.7 million in 2030 and 131.5 million in 2030 
[23]. AD is one of the most costly diseases to cure 
in developed countries [24]. This cholinergic 
change is believed to represent the earliest 
determined neurochemical event leading to AD 
[25]. Two major hypotheses have been proposed 
regarding the molecular mechanism of the 
pathogenesis of AD: the cholinergic hypothesis and 
the amyloid cascade hypothesis. In order to treat 
and prevent AD, most pharmacological research 
has focused on AChE and BChE inhibitors to 
alleviate the cholinergic deficit and to improve 
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neurotransmission [26]. AChE is the main enzyme 
responsible for the hydrolysis of ACh at the 
cholinergic synapse, while BChE acts as a co-
regulator of the activity of AChE. Under normal 
physiological conditions, maximum ChEs activity 
is due to AChE. However, as the disease progress, 
AChE activity decreases in specific brain regions, 
whereas BChE activity increases, compensating for 
some of the functions of AChE in cholinergic 
neurons. Consequently, therapeutic agents that 
serve as inhibitors of both these enzymes could 
provide additional benefits in AD [27]. Moreover, 
considerable evidence from genetics and molecular 
biology supports the “amyloid-cascade 
hypothesis,” which states that Aβ production and 
excessive accumulation are the principal 
pathogenetic events leading to AD [28]. BACE1 is 
the rate-limiting enzyme in the proteolytic 
processing of APP and is required for the 
production of Aβ. BACE1 levels and activities are 
increased in AD [29,30]. Furthermore, BACE1 
which is involved in the first and rate-limiting step 
of Aβ formation from APP, has also generated 
great interest and several BACE1 inhibitors are 
currently being studied in clinical trials [31]. AD 
continues to be described as highly connected with 
cellular oxidative stress, which includes 
augmentation of protein oxidation, protein 
nitration, glycol oxidation, and lipid oxidation 
together with the accumulation of Aβ [32,33]. 
Among cellular oxidative stress, ONOO-, have 
been associated with the etiology of several human 
degenerative disorders. Particularly, ONOO-, 
produced by the in vivo reaction of nitric oxide 
(NO) with O2-, has been implicated in Aβ 
formation and accumulation, with high levels of Aβ 
also augmenting ONOO- generation in the brain of 
AD patients [34]. 
Ocimum sanctum L. (Lamiaceae), a well-known 
herbal medicine, is widely distributed throughout 
the world [13]. Its leaves have long been used to 
treat a variety of ailments, including ozena, skin 
diseases, and gastric and hepatic disorders and are 
used as a diaphoretic, an antiperiodic, and an 
expectorant. Several types of constituents have 
been isolated from O. sanctum including 
terpenoids, phenolic derivatives, hydroxycinnamic 
acid derivatives, benzoic acid derivatives, 
flavonoids and their glycosides, and eugenol and 
eugenol glycosides. Some of these compounds 
have been reported to exhibit antioxidant, 
antimicrobial, anti-inflammatory, antistress, 
anthelmintic, and radio-protective activities [35-
38]. O. sanctum shows ameliorative potential in 
attenuating vincristine induced peripheral 
neuropathic pain in rats, which may be attributed to 
decrease in oxidative stress and calcium levels. 
Administration of OS (100 and 200 mg/kg p.o.) 
and its saponin rich fraction (100 and 200 mg/kg 
p.o.) for 14 days significantly attenuated 
vincristine-induced neuropathic pain along with 
decrease in oxidative stress and calcium levels 
[20]. Giridharan et al. reported that O. sanctum 
Linn. Leaf extracts inhibit acetylcholinesterase and 
improve cognition in rats with experimentally 
induced dementia. O. sanctum treatment 
significantly increased the induration in the DNCB 
skin test. Therefore, O. sanctum was shown to be 
useful for the management 
of experimentally induced cognitive dysfunctions 
in rats [39]. In Morris water maze test, OS 
pretreatment improves reference memory, working 
memory and spatial learning. Both ibotenic acid 
and colchicine induced deficits in active avoidance 
learning and retention of learned behavior were 
significantly reversed. OS might be effective in 
clinical Alzheimer’s disease by virtue of its 
cognition enhancement, antidepressant and 
antianxiety properties, which are primary needs to 
be addressed in alzheimer’s disease [40]. In our 
present study, we found that ethanol extract of O. 
sanctum showed potent inhibitory activities against 
AChE, BChE, BACE1, and antioxidant scavenging 
activity. Among the tested fractions, CH2Cl2 
fraction showed potential activity compared to 
other polar fractions. The CH2Cl2 fraction was 
found as the most active fraction by AChE, BChE 
and BACE1 inhibitory assays. The CH2Cl2 fraction 
was also shown to possess strong inhibitory 
activities against peroxynitrite (ONOO-) 
scavenging assay. Considering the inhibitory 
potential, CH2Cl2 fraction was selected for 
chromatographic separation in order to determine 
the active compounds from O. sanctum. Repeated 
chromatography of the CH2Cl2 fraction yielded two 
flavonoid compounds, Cirsilineol and isothymusin, 
was found to be the most active compound in the 
AChE, BChE and BACE1 inhibitory assays as well 
as ONOO- inhibitory assay. Therefore, our results 
clearly demonstrated that O. sanctum and its 
constituent have great value in the development of 
therapeutic and preventing agents for AD. Further 
in vivo and cell-based studies are needed to clarify 
the detailed mechanism of action of these 




The present bioactivity-guided fractionation and 
isolation study of O. sanctum on BACE1 and ChEs 
inhibition demonstrated that the isolated 
constituents exerted potential BACE1 along with 
ChEs inhibitory effects, and ONOO- scavenging 
effect, suggesting their potential role for treating 
AD. In particular, the AChE, BChE, BACE1 along 
with ONOO- inhibitory activities of the isolated 
compounds were investigated for the first time. The 
findings of the present study demonstrated that O. 
sanctum and its isolated constituents might act as a 
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therapeutic or preventive agent for AD by 
alleviating oxidative stress 
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